Drug intelligence / Profile preview

NWL-PSCs

Development stage: Preclinical
Lead developer: New World Laboratories
Modality: Stem Cell Therapies → Cell Therapies

Overview

NWL-PSCs is a preclinical-stage autologous cell therapy being developed by New World Laboratories for the treatment of metabolic and pancreatic diseases, most notably diabetes. Utilizing a proprietary personalized stem cell platform, the therapy involves the direct reprogramming of a patient's own somatic cells into pancreatic stem-like cells. This approach is designed to facilitate pancreatic tissue regeneration and provide a functional source of autologous islet beta-cells to restore insulin production. By using patient-derived cells, the therapy aims to avoid the immunological rejection associated with allogeneic transplants and the ethical concerns surrounding fetal or embryonic-derived stem cells.

Other names: Pancreatic Stem-like Cells

Beyond the preview

Go deeper on NWL-PSCs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NWL-PSCs.

Explore the full profile